Alnylam Pharmaceuticals Inc., of Cambridge, Mass., reported its global net product revenues for the fourth quarter were $12.1 million for Onpattro (patisiran), to treat hereditary transthyretin-mediated amyloidosis, and $12.5 million for the full year.